IPCA Laboratories Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- ✓Strong return on equity (ROE 15.7%)
- ✓Efficient capital deployment (ROCE 17%)
- ✓Attractively valued vs sector (P/E 40.9x vs industry 54.4x)
- ✓Low debt relative to equity (D/E 0.1x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,944 | ₹4.6L Cr | 37.3 | 5.59 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹7,388 | ₹1.9L Cr | 73.4 | 11.71 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹5,040 | ₹1.6L Cr | 73.6 | 20.32 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,939 | ₹1.3L Cr | 64.9 | 13.56 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,416 | ₹1.1L Cr | 30.1 | 3.32 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,123 | ₹1.1L Cr | 21 | 4.17 | 21.2 | 21.1 | 0.38 |
| LUPIN Lupin Limited | ₹2,405 | ₹1.1L Cr | 19.6 | 4.9 | 28.7 | 29.9 | 0.32 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
IPCALAB · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 46.29% | 46.30% | 46.30% | 46.30% | 44.72% | 44.72% |
| FII | 10.27% | 10.51% | 10.85% | 10.83% | 11.06% | 10.75% |
| DII | 34.19% | 34.05% | 33.46% | 33.90% | 35.36% | 35.73% |
| Public | 8.93% | 8.82% | 9.07% | 8.64% | 8.53% | 8.45% |
| Govt | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% | 0.32% |
Corporate Events
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Dividend - Rs 2 Per Share
Interim Dividend - Rs 2 Per Share
Annual General Meeting/Dividend - Rs 2 Per Share
Interim Dividend - Rs 2 Per Share
Latest News
All news →IPCA Laboratories receives credit rating update
*IPCA Laboratories receives credit rating update.* The company’s latest credit assessment has been filed with the exchange. **No financial figures or rating changes** were detailed in the headline. Further specifics are expected in the full report. 📊 *STOCKS:* IPCALAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #credit_rating
IPCA Labs publishes mandatory newspaper notice
*IPCA Labs publishes mandatory newspaper notice.* This is a routine corporate filing requirement with no material business update. Such notices are typically issued for regulatory or legal disclosures. No financial or operational impact is expected. 📊 *STOCKS:* IPCALABORATORY | 🏢 *SECTOR:* Pharma | #LOWIMPACT #corporatefiling
IPCA Labs files Business Responsibility and Sustainability Report
*IPCA Labs files Business Responsibility and Sustainability Report.* This is a routine regulatory disclosure under BRSR norms. No financial impact or operational updates disclosed. 📊 *STOCKS:* IPCALABORATORY | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Sustainability
IPCA Labs publishes mandatory newspaper notice
*IPCA Labs publishes mandatory newspaper notice*. IPCA Laboratories Limited has released a copy of its newspaper publication as part of regulatory requirements. The filing contains no new financial or operational details. Such disclosures are routine and do not impact business operations. 📊 *STOCKS:* IPCALAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulatory
IPCA Laboratories publishes mandatory newspaper notice
*IPCA Laboratories publishes mandatory newspaper notice.* This is a routine regulatory disclosure required under corporate norms. Such filings are standard and do not indicate operational or financial changes. Investors need not take action. 📊 *STOCKS:* IPCALAB | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Regulatory
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2.4K Cr ▼6.4% | ₹2.6K Cr ▲10.7% | ₹2.3K Cr ▲2.8% | ₹2.2K Cr ▲0.1% | ₹2.2K Cr ▼4.7% | ₹2.4K Cr ▲12.5% | ₹2.1K Cr ▲3.0% | ₹2.0K Cr |
| Op. Profit | ₹533 Cr ▼2.2% | ₹545 Cr ▲31.0% | ₹416 Cr ▼3.0% | ₹429 Cr ▼7.3% | ₹463 Cr ▲5.0% | ₹441 Cr ▲12.2% | ₹393 Cr ▲22.0% | ₹322 Cr |
| OPM | 22.0% ▲4.8% | 21.0% ▲16.7% | 18.0% ▼5.3% | 19.0% ▼9.5% | 21.0% ▲10.5% | 19.0% ▲0.0% | 19.0% ▲18.8% | 16.0% |
| Net Profit | ₹364 Cr ▲29.5% | ₹281 Cr ▲20.6% | ₹233 Cr ▲264.1% | ₹64 Cr ▼76.8% | ₹276 Cr ▲12.2% | ₹246 Cr ▲23.6% | ₹199 Cr ▲19800.0% | ₹1 Cr |
| EPS (₹) | 12.86 ▲15.4% | 11.14 ▲21.2% | 9.19 ▲244.2% | 2.67 ▼72.7% | 9.78 ▲8.1% | 9.05 ▲19.4% | 7.58 ▲222.6% | 2.35 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹9.6K Cr ▲7.9% | ₹8.9K Cr ▲16.1% | ₹7.7K Cr ▲23.5% | ₹6.2K Cr ▲7.0% | ₹5.8K Cr ▲7.5% | ₹5.4K Cr ▲16.8% | ₹4.6K Cr ▲23.3% | ₹3.7K Cr ▲15.0% | ₹3.3K Cr ▲3.2% | ₹3.2K Cr |
| Expenses | ₹7.6K Cr ▲6.2% | ₹7.2K Cr ▲13.1% | ₹6.3K Cr ▲20.2% | ₹5.3K Cr ▲17.9% | ₹4.5K Cr ▲16.4% | ₹3.8K Cr ▲3.4% | ₹3.7K Cr ▲21.8% | ₹3.1K Cr ▲8.8% | ₹2.8K Cr ▲3.6% | ₹2.7K Cr |
| Op. Profit | ₹2.0K Cr ▲15.0% | ₹1.7K Cr ▲30.7% | ₹1.3K Cr ▲42.1% | ₹932 Cr ▼29.7% | ₹1.3K Cr ▼14.6% | ₹1.6K Cr ▲71.7% | ₹904 Cr ▲30.1% | ₹695 Cr ▲52.7% | ₹455 Cr ▲0.9% | ₹451 Cr |
| OPM | 21.0% ▲10.5% | 19.0% ▲11.8% | 17.0% ▲13.3% | 15.0% ▼34.8% | 23.0% ▼20.7% | 29.0% ▲45.0% | 20.0% ▲5.3% | 19.0% ▲35.7% | 14.0% ▲0.0% | 14.0% |
| Other Income | ₹80 Cr ▲170.2% | ₹-114 Cr ▼770.6% | ₹17 Cr ▼86.2% | ₹123 Cr ▲127.8% | ₹54 Cr ▼8.5% | ₹59 Cr ▼9.2% | ₹65 Cr ▲16.1% | ₹56 Cr ▲36.6% | ₹41 Cr ▲272.7% | ₹11 Cr |
| Interest | ₹79 Cr ▼10.2% | ₹88 Cr ▼37.6% | ₹141 Cr ▲193.8% | ₹48 Cr ▲336.4% | ₹11 Cr ▼8.3% | ₹12 Cr ▼40.0% | ₹20 Cr ▼9.1% | ₹22 Cr ▼21.4% | ₹28 Cr ▲3.7% | ₹27 Cr |
| Depreciation | ₹418 Cr ▲5.0% | ₹398 Cr ▲11.5% | ₹357 Cr ▲36.3% | ₹262 Cr ▲12.9% | ₹232 Cr ▲11.0% | ₹209 Cr ▼0.5% | ₹210 Cr ▲15.4% | ₹182 Cr ▲2.2% | ₹178 Cr ▲2.9% | ₹173 Cr |
| PBT | ₹1.6K Cr ▲39.1% | ₹1.1K Cr ▲34.2% | ₹843 Cr ▲13.2% | ₹745 Cr ▼34.4% | ₹1.1K Cr ▼18.2% | ₹1.4K Cr ▲88.0% | ₹739 Cr ▲35.3% | ₹546 Cr ▲87.6% | ₹291 Cr ▲11.1% | ₹262 Cr |
| Tax % | 24.0% ▼20.0% | 30.0% ▼18.9% | 37.0% ▲8.8% | 34.0% ▲70.0% | 20.0% ▲17.6% | 17.0% ▼5.6% | 18.0% ▼5.3% | 19.0% ▲5.6% | 18.0% ▼30.8% | 26.0% |
| Net Profit | ₹1.2K Cr ▲50.8% | ₹785 Cr ▲50.1% | ₹523 Cr ▲9.2% | ₹479 Cr ▼46.2% | ₹890 Cr ▼22.0% | ₹1.1K Cr ▲88.9% | ₹604 Cr ▲36.7% | ₹442 Cr ▲84.9% | ₹239 Cr ▲22.6% | ₹195 Cr |
| EPS (₹) | 44.98 ▲54.7% | 29.08 ▲34.8% | 21.57 ▲16.1% | 18.58 ▼46.7% | 34.85 ▼22.5% | 44.94 ▲87.3% | 23.99 ▲36.3% | 17.6 ▲85.5% | 9.49 ▲23.1% | 7.71 |
| Div Payout | 0.0% ▼100.0% | 14.0% ▼26.3% | 19.0% ▼13.6% | 22.0% ▲100.0% | 11.0% ▲22.2% | 9.0% ▼10.0% | 10.0% ▲11.1% | 9.0% ▲80.0% | 5.0% ▼16.7% | 6.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹25 Cr ▲0.0% | ₹25 Cr ▲0.0% | ₹25 Cr ▲0.0% | ₹25 Cr ▲0.0% | ₹25 Cr ▲0.0% | ₹25 Cr ▲0.0% | ₹25 Cr ▲0.0% | ₹25 Cr ▲0.0% | ₹25 Cr ▲0.0% | ₹25 Cr |
| Reserves | ₹7.4K Cr ▲6.9% | ₹6.9K Cr ▲9.8% | ₹6.3K Cr ▲8.4% | ₹5.8K Cr ▲6.4% | ₹5.5K Cr ▲16.9% | ₹4.7K Cr ▲29.8% | ₹3.6K Cr ▲16.3% | ₹3.1K Cr ▲16.3% | ₹2.7K Cr ▲9.6% | ₹2.4K Cr |
| Borrowings | ₹1.3K Cr ▼6.2% | ₹1.4K Cr ▼5.2% | ₹1.4K Cr ▼2.9% | ₹1.5K Cr ▲83.5% | ₹807 Cr ▲204.5% | ₹265 Cr ▼47.1% | ₹501 Cr ▲7.7% | ₹465 Cr ▼26.0% | ₹628 Cr ▼12.3% | ₹716 Cr |
| Other Liabilities | ₹3.6K Cr ▲3.6% | ₹3.4K Cr ▲3.2% | ₹3.3K Cr ▲155.8% | ₹1.3K Cr ▼2.8% | ₹1.3K Cr ▲21.7% | ₹1.1K Cr ▼2.7% | ₹1.1K Cr ▲17.6% | ₹961 Cr ▲20.3% | ₹799 Cr ▲1.4% | ₹788 Cr |
| Total Liabilities | ₹12.3K Cr ▲4.4% | ₹11.7K Cr ▲5.8% | ₹11.1K Cr ▲28.7% | ₹8.6K Cr ▲12.9% | ₹7.6K Cr ▲25.9% | ₹6.1K Cr ▲15.4% | ₹5.3K Cr ▲15.6% | ₹4.5K Cr ▲10.5% | ₹4.1K Cr ▲3.9% | ₹4.0K Cr |
| Assets | ||||||||||
| Fixed Assets | ₹4.4K Cr ▲2.4% | ₹4.3K Cr ▼6.3% | ₹4.6K Cr ▲65.5% | ₹2.8K Cr ▲13.8% | ₹2.4K Cr ▲16.7% | ₹2.1K Cr ▲0.6% | ₹2.1K Cr ▲6.1% | ₹1.9K Cr ▼0.7% | ₹2.0K Cr ▼1.5% | ₹2.0K Cr |
| CWIP | ₹777 Cr ▲24.9% | ₹622 Cr ▲81.3% | ₹343 Cr ▲145.0% | ₹140 Cr ▼54.2% | ₹306 Cr ▲30.2% | ₹235 Cr ▲76.7% | ₹133 Cr ▲101.5% | ₹66 Cr ▼9.6% | ₹73 Cr ▼23.2% | ₹95 Cr |
| Investments | ₹1.2K Cr ▲22.8% | ₹980 Cr ▲13.7% | ₹862 Cr ▲37.7% | ₹626 Cr ▼36.7% | ₹989 Cr ▲95.8% | ₹505 Cr ▲62.9% | ₹310 Cr ▲158.3% | ₹120 Cr ▲37.9% | ₹87 Cr ▼36.0% | ₹136 Cr |
| Other Assets | ₹5.9K Cr ▲0.6% | ₹5.9K Cr ▲10.0% | ₹5.3K Cr ▲4.6% | ₹5.1K Cr ▲30.1% | ₹3.9K Cr ▲20.6% | ₹3.3K Cr ▲18.1% | ₹2.8K Cr ▲13.8% | ₹2.4K Cr ▲20.9% | ₹2.0K Cr ▲14.7% | ₹1.7K Cr |
| Total Assets | ₹12.3K Cr ▲4.4% | ₹11.7K Cr ▲5.8% | ₹11.1K Cr ▲28.7% | ₹8.6K Cr ▲12.9% | ₹7.6K Cr ▲25.9% | ₹6.1K Cr ▲15.4% | ₹5.3K Cr ▲15.6% | ₹4.5K Cr ▲10.5% | ₹4.1K Cr ▲3.9% | ₹4.0K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹1.3K Cr ▲39.8% | ₹945 Cr ▲17.2% | ₹806 Cr ▼5.8% | ₹856 Cr ▼21.5% | ₹1.1K Cr ▲91.2% | ₹570 Cr ▲13.8% | ₹501 Cr ▲46.9% | ₹341 Cr ▲20.9% | ₹282 Cr ▼60.2% | ₹709 Cr |
| Investing CF | ₹-870 Cr ▲28.4% | ₹-1.2K Cr ▼67.6% | ₹-725 Cr ▲14.8% | ₹-851 Cr ▼63.3% | ₹-521 Cr ▼2.4% | ₹-509 Cr ▼208.5% | ₹-165 Cr ▼22.2% | ₹-135 Cr ▲9.4% | ₹-149 Cr ▲31.7% | ₹-218 Cr |
| Financing CF | ₹-283 Cr ▲48.8% | ₹-553 Cr ▼209.1% | ₹507 Cr ▲18.7% | ₹427 Cr ▲239.5% | ₹-306 Cr ▼123.4% | ₹-137 Cr ▲25.1% | ₹-183 Cr ▼40.8% | ₹-130 Cr ▲18.2% | ₹-159 Cr ▲65.6% | ₹-462 Cr |
| Net Cash Flow | ₹169 Cr ▲120.5% | ₹-823 Cr ▼240.0% | ₹588 Cr ▲36.1% | ₹432 Cr ▲63.6% | ₹264 Cr ▲447.4% | ₹-76 Cr ▼149.7% | ₹153 Cr ▲104.0% | ₹75 Cr ▲388.5% | ₹-26 Cr ▼189.7% | ₹29 Cr |
| Free Cash Flow | ₹551 Cr ▲1.5% | ₹543 Cr ▲56.5% | ₹347 Cr ▼8.7% | ₹380 Cr ▼48.0% | ₹731 Cr ▲163.9% | ₹277 Cr ▼14.0% | ₹322 Cr ▲56.3% | ₹206 Cr ▲40.1% | ₹147 Cr ▼68.3% | ₹463 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 77d ▼3.8% | 80d ▲37.9% | 58d ▲1.8% | 57d ▲3.6% | 55d ▼22.5% | 71d ▲7.6% | 66d ▼1.5% | 67d ▲15.5% | 58d ▲1.8% | 57d |
| Inventory Days | 336d ▼4.0% | 350d ▲26.8% | 276d ▼18.1% | 337d ▲0.0% | 337d ▲14.6% | 294d ▼7.0% | 316d ▲10.5% | 286d ▼1.4% | 290d ▲0.3% | 289d |
| Days Payable | 111d ▲0.9% | 110d ▲32.5% | 83d ▼17.8% | 101d ▼27.9% | 140d ▲3.7% | 135d ▼12.3% | 154d ▲12.4% | 137d ▲5.4% | 130d ▼10.3% | 145d |
| Cash Conv. Cycle | 302d ▼5.9% | 321d ▲27.9% | 251d ▼14.3% | 293d ▲16.7% | 251d ▲9.6% | 229d ▲0.4% | 228d ▲5.6% | 216d ▼0.9% | 218d ▲9.0% | 200d |
| Working Capital Days | 101d ▼9.0% | 111d ▲56.3% | 71d ▼30.4% | 102d ▼1.0% | 103d ▲17.0% | 88d ▲0.0% | 88d ▲10.0% | 80d ▲8.1% | 74d ▲21.3% | 61d |
| ROCE | 15.0% ▲15.4% | 13.0% ▲18.2% | 11.0% ▼45.0% | 20.0% ▼35.5% | 31.0% ▲63.2% | 19.0% ▲18.8% | 16.0% ▲60.0% | 10.0% ▲11.1% | 9.0% ▲80.0% | 5.0% |
Source: Screener.in · Lower days = better efficiency
About IPCA Laboratories Limited
Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)
Healthcare · Pharmaceuticals & Biotechnology